Study of talabostat and cisplatin in advanced melanoma

Journal of Drugs in Dermatology, Sept-Oct, 2005

This study is currently recruiting patients. Sponsored by Point Therapeutics. The purpose of this study is to assess the antitumor activity and safety of the combination of talabostat and cisplatin in patients with metastatic melanoma.

Condition    Treatment or Intervention          Phase

Melanoma     Drug: talabostat (PT-100) tablets  Phase II
Skin Cancer  Drug: cisplatin

Study ID Numbers: PTH-303

ClinicalTrials.gov Identifier: NCT00083252